Save to Existing Project
Save to a New Project
Yeda R&D Co. Ltd
Abstract ID: 1633
The ErbB family consists of four structurally related receptor tyrosine kinases. Excessive ErbB signalling is associated with enhanced tumorogenesis, and as such serves as a major therapeutic target...
The ErbB family consists of four structurally related receptor tyrosine kinases. Excessive ErbB signalling is associated with enhanced tumorogenesis, and as such serves as a major therapeutic target in a wide array of solid tumour cancers. A member of this family, the human epidermal growth factor receptor 2 (ErbB-2/HER2), is overexpressed in a variety of human cancers, including breast and gastric tumours. ErbB-2/HER2 amplification correlates with elevated metastatic activity and poor prognosis.
An innovative and highly potent approach for cancer treatment is proposed here, based on delivering novel nucleic acid-based entities called aptamers targeting ErbB-2/HER2.
Aptamers are single-stranded oligonucleotides that fold into defined architectures and avidly bind to targets such as proteins, with the same effectiveness and affinity associated with mAbs. Using a novel screening technology the research team has identified a multimeric aptamer with pronounced ErbB-2/HER2 inhibitory activity. Preliminary preclinical experiments show that treatment of gastric tumour-bearing mice with trimeric aptamer resulted in reduced tumour growth that was nearly twofold stronger than that achieved with a monoclonal anti-ErbB-2/HER2 antibody.
Remarkably, the antitumor effect exerted by the multimeric anti-ErbB-2/HER2 aptamers is twofold stronger than that elicited by currently available antiErbB-2 monocolonal antibodies.
Please enquire quoting reference no. 1633 regarding licensing or codevelopment partnerships.
Last Updated May 2015